Concerning disease-related antibodies, 75% of participants with scleroderma (36/48) tested positive for Scl-70 antibodies, 8.33% (4/48) had positive anti-ACA antibodies, 10.42% (5/48) had anti-PM/Scl antibodies, 14.58% (7/48) had anti-SS-A antibodies, 10.42% (5/48) had anti-SS-B antibodies, 6.25% (3/48) had anti-Jo-1 antibodies, one participant had anti-Mi-2 antibodies, one participant had anti-Sm antibodies, one participant had anti-AMA-M2 antibodies, and one participant had anti-RNP/Sm antibodies. This evidence concerns the gene PRB1 and scleroderma.